When life-threatening pustules suddenly erupt across the body accompanied by systemic inflammation, generalized pustular psoriasis (GPP) patients face a medical crisis with few treatment options.
Editor’s Note: This story share was submitted by Beverly Smith, a retired schoolteacher from Canada. I was diagnosed after treatment for PTSD and having had
As featured on KFF News, Heidi DiLorenzo was preparing to welcome her second child, and her biggest concern wasn’t taking Zoloft. The Birmingham attorney had
Eccogene, a clinical-stage biopharmaceutical company, has announced enrollment of the first patient in MOSAIC, a Phase 2a clinical trial investigating two novel oral small molecules
Editor’s Note: This poem, originally written by Spence Shishido, was shared with Patient Worthy by our friends at Elephants & Tea. To see the poem
This charity has been set up to offer research based and lived experience, advice and support. Aims: To support any individual of any age with
As reported by Healio, the U.S. Food and Drug Administration (FDA) has officially qualified AIM-MASH AI Assist, marking a milestone as the first artificial intelligence
Sixteen years ago, Nate Appleman, a celebrated chef, faced every parent’s worst nightmare when his two-year-old son, Oliver, fell ill. Oliver’s diagnosis was a complete
My name is Jessica Glaspie, and I have been living with HIV for over 15 years! A lot of people think that life and love
GSK announced a significant milestone in respiratory medicine as the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of
Lumos Labs has received FDA 510(k) approval for LumosityRx, a prescription version of its well-known Lumosity brain training platform. As reported by Fierce BioTech, The
“We’re going to Disney World!” That’s what all the winners say, right? When the big game is over and the team has won the championship,
Eli Lilly presented compelling clinical evidence positioning its BTK inhibitor Jaypirca as a potentially superior treatment option compared to the established blood cancer therapy Imbruvica,
In a recent statement, The U.S. Food and Drug Administration (FDA) has introduced the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot, a groundbreaking initiative aimed at
In a statement by the FDA, the U.S. Food and Drug Administration has authorized Waskyra (etuvetidigene autotemcel), the first gene therapy designed to treat Wiskott-Aldrich
The biotech sector witnessed significant momentum as four clinical-stage companies announced compelling data across muscular dystrophy, immunology, and obesity treatment areas, triggering substantial stock market
As reported by MedicalXpress, Researchers have uncovered a surprising immune function in specialized intestinal cells that may reshape our understanding of gut health and autoimmune
Genentech announced landmark clinical trial results demonstrating that giredestrant, an investigational selective estrogen receptor degrader (SERD), significantly outperforms standard endocrine therapy in treating early-stage ER-positive
Vasculitis FoundationManaging vasculitis is about more than treating symptoms
It’s about building the right care team, monitoring your health long term, and feeling confident speaking up during appointments.
Our free fact sheet, Living Well with Vasculitis: Essential Topics to Discuss with Your Provider, helps patients and caregivers prepare for meaningful conversations about treatment, relapse monitoring, mental health, lifestyle changes, and more.
Take an active role in your care.
👉 Read the full resource and download the fact sheet at hov.to/7f6817ea
Bolniki z Marfanovim sindromom so si med seboj zelo različni, čeprav imajo isto bolezen, ker bolezen povzročajo različne mutacije istega gena FBN1, ki lahko vodijo v različno hude oblike bolezni. Poleg tega se bolezen pri posameznikih različno izraža, saj se znaki lahko pojavijo v različni starosti, z različno resnostjo in prizadenejo različne organske sisteme. Na potek bolezni vplivajo tudi drugi geni, ki lahko okrepijo ali omilijo učinek osnovne mutacije, ter okoljski in življenjski dejavniki, kot so telesna aktivnost, način življenja in pravočasnost zdravljenja. K razlikam med bolniki prispevajo tudi naključni biološki procesi v razvoju in delovanju telesa.
#MarfanovSindrom #redkebolezni #medicina #zdravje #bolnik #bolezen #FBN1 #vezivnotkivo #srce #skelet #organi #aorta #zaklopke #pljuca #gen #genetik #genetika #zdravljenje
Brittle Bone SocietyNew blog! ✨
We are excited to introduce our first new blogger of 2026, Deirdre Anderson! Deirdre's first blog looks back at her childhood experiences of icy conditions and how this shaped her attitude towards winter that continues into adulthood. Despite decades without a fracture, the impact of early experiences with Osteogenesis Imperfecta still influences how she navigates winter today.
Read Deirdre's blog here: www.brittlebone.org/stories/deirdres-story-winter-months-and-oi/ 💙
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
